

Dominique Guyader

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11949940/publications.pdf>

Version: 2024-02-01

70
papers

6,457
citations

94433

37
h-index

85541

71
g-index

72
all docs

72
docs citations

72
times ranked

6308
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin resistance-associated hepatic iron overload. <i>Gastroenterology</i> , 1999, 117, 1155-1163.	1.3	461
2	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	13.7	449
3	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. <i>Gastroenterology</i> , 2017, 152, 142-156.e2.	1.3	420
4	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	3.7	407
5	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	3.7	401
6	Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. <i>Gastroenterology</i> , 1998, 115, 929-936.	1.3	306
7	Liver pathology in genetic hemochromatosis: A review of 135 homozygous cases and their bioclinical correlations. <i>Gastroenterology</i> , 1992, 102, 2050-2059.	1.3	299
8	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. <i>Lancet, The</i> , 2015, 385, 1075-1086.	13.7	281
9	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases, The</i> , 2015, 15, 397-404.	9.1	267
10	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232
11	Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases. <i>Hepatology</i> , 2006, 44, 472-477.	7.3	211
12	Primary liver cancer in genetic hemochromatosis: A clinical, pathological, and pathogenetic study of 54 cases. <i>Gastroenterology</i> , 1993, 104, 228-234.	1.3	201
13	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	1.3	183
14	Fibrillar collagen scoring by second harmonic microscopy: A new tool in the assessment of liver fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 398-406.	3.7	157
15	Histologic Features of the Liver in Insulin Resistance-Associated Iron Overload. <i>American Journal of Clinical Pathology</i> , 2001, 116, 263-270.	0.7	132
16	Liver fibrosis in genetic hemochromatosis. <i>Journal of Hepatology</i> , 1992, 16, 122-127.	3.7	128
17	Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. <i>Hepatology</i> , 2002, 36, 673-678.	7.3	118
18	Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. <i>Journal of Hepatology</i> , 2000, 32, 727-733.	3.7	103

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	3.7	100
20	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. <i>Gastroenterology</i> , 2019, 156, 997-1009.e5.	1.3	100
21	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 5	7.3	96
22	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	1.3	81
23	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	3.7	79
24	A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. <i>Journal of Hepatology</i> , 1999, 30, 588-593.	3.7	78
25	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	7.3	75
26	Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. <i>Liver International</i> , 2017, 37, 1314-1324.	3.9	68
27	Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2007, 46, 587-595.	3.7	67
28	Effect of alcohol consumption on liver stiffness measured by transient elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 516.	3.3	62
29	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 5	12.1	59
30	Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. <i>Journal of Hepatology</i> , 2014, 60, 245-252.	3.7	58
31	Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. <i>Journal of Hepatology</i> , 2011, 54, 1130-1136.	3.7	57
32	Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. <i>Hepatology</i> , 2004, 39, 1639-1646.	7.3	54
33	Personalized surveillance for hepatocellular carcinoma in cirrhosis " using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	3.7	52
34	Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis. <i>Journal of Hepatology</i> , 1992, 15, 304-308.	3.7	51
35	Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. <i>Journal of Hepatology</i> , 2015, 62, 682-689.	3.7	51
36	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	2.7	49

#	ARTICLE	IF	CITATIONS
37	A robust collagen scoring method for human liver fibrosis by second harmonic microscopy. <i>Optics Express</i> , 2010, 18, 25794.	3.4	40
38	Noninvasive assessment of liver fibrosis in C282Y homozygous <sc>HFE</sc> hemochromatosis. <i>Liver International</i> , 2015, 35, 1731-1738.	3.9	39
39	Clinical aspects of hemochromatosis. <i>Transfusion Science</i> , 2000, 23, 193-200.	0.6	35
40	A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. <i>Journal of Hepatology</i> , 2012, 56, 334-340.	3.7	34
41	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	7.3	33
42	Worse Outcomes of Patients With HFE Hemochromatosis With Persistent Increases in Transferrin Saturation During Maintenance Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1620-1627.	4.4	32
43	Hemochromatosis after the gene discovery: revisiting the diagnostic strategy. <i>Journal of Hepatology</i> , 1998, 28, 14-18.	3.7	28
44	Magnetic Resonance Iron-Free Nodules in Genetic Hemochromatosis. <i>American Journal of Gastroenterology</i> , 1999, 94, 1083-1086.	0.4	22
45	Pretransplant renal function according to <sc>CKD</sc>â€<sc>EPI</sc> cystatin C equation is a prognostic factor of death after liver transplantation. <i>Liver International</i> , 2016, 36, 547-554.	3.9	22
46	Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon Î±-2a and Ribavirin in Patients With Hepatitis C. <i>Journal of Infectious Diseases</i> , 2011, 204, 601-608.	4.0	19
47	Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 290-291.	4.4	16
48	Nonvirological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of <sc>ANRS CO</sc>12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	2.0	16
49	Reduced phenotypic expression in genetic hemochromatosis with time: Role of exposure to non-genetic modifiers. <i>Journal of Hepatology</i> , 2019, 70, 118-125.	3.7	15
50	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	4.9	15
51	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon Î±-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436.	3.2	13
52	Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1542-1552.e6.	4.4	10
53	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	1.5	10
54	Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 39-50.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 677-689.	2.9	6
56	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	2.9	6
57	Long-term course after initial iron removal of iron excess in patients with dysmetabolic iron overload syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 418-421.	1.6	5
58	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	2.9	5
59	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101459.	1.5	4
60	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. <i>JHEP Reports</i> , 2021, 3, 100285.	4.9	4
61	Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon- α 2a (40 KD) plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 927-932.	1.0	3
62	Chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 164-172.	1.6	3
63	Iron metabolism imbalance at the time of listing increases overall and infectious mortality after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 1938-1949.	3.3	3
64	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	4.9	3
65	Computed tomography and magnetic resonance imaging in the diagnosis of hemochromatosis. , 2000, , 219-226.		2
66	Steatosis, iron and HFE genes. <i>Journal of Hepatology</i> , 2008, 48, 514-515.	3.7	2
67	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. <i>Cancer Prevention Research</i> , 2021, 14, 581-592.	1.5	2
68	ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. <i>Liver International</i> , 2022, 42, 1386-1400.	3.9	2
69	Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 39-50.	2.5	1
70	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. <i>Journal of Cannabis Research</i> , 2022, 4, .	3.2	1